Literature DB >> 9754058

Central nervous system depressant activities of melatonin in rats and mice.

A V Shaji1, S K Kulkarni.   

Abstract

Melatonin (10 and 20 mg/kg) potentiated pentobarbitone (45 mg/kg) induced hypnosis; it (50 and 100 mg/kg) decreased both total and ambulatory activity; produced (10, 25 and 50 mg/kg) hypothermia and possessed (10-400 mg/kg) significant analgesic property both in tail-flick and acetic acid-induced writhing tests. Melatonin in low dose (10 mg/kg) significantly reduced the forced-swimming induced immobility period per se and also reserpine induced immobility. While the antinociceptive effect of melatonin was sensitive to reversal by naloxone (2 mg/kg), other CNS depressant profile resembled the effects of benzodiazepines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9754058

Source DB:  PubMed          Journal:  Indian J Exp Biol        ISSN: 0019-5189            Impact factor:   0.818


  4 in total

1.  Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models.

Authors:  Shao-wen Tian; Moshe Laudon; Li Han; Jun Gao; Fu-lian Huang; Yu-feng Yang; Hai-feng Deng
Journal:  Acta Pharmacol Sin       Date:  2010-06-28       Impact factor: 6.150

2.  Dietary DHA during development affects depression-like behaviors and biomarkers that emerge after puberty in adolescent rats.

Authors:  Michael J Weiser; Kelly Wynalda; Norman Salem; Christopher M Butt
Journal:  J Lipid Res       Date:  2014-11-19       Impact factor: 5.922

3.  Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors.

Authors:  Michel Bourin; Elisabeth Mocaër; Roger Porsolt
Journal:  J Psychiatry Neurosci       Date:  2004-03       Impact factor: 6.186

4.  Antidepressant-like effects of agomelatine, melatonin and the NK1 receptor antagonist GR205171 in impulsive-related behaviour in rats.

Authors:  Florence Loiseau; Claudine Le Bihan; Michel Hamon; Marie-Hélène Thiébot
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.